Shareholders Applaud ViiV Healthcare for Sharing its Patent to Vital Pediatric HIV Drug

Decision to enter the Medicines Patent Pool (MPP) with abacavir will allow for low-cost manufacture, increasing access to life-saving medication for millions of children worldwide

New York, New York – Today, shareholders of the parent companies of ViiV Healthcare–a joint venture of GlaxoSmithKline (GSK), Pfizer and Shionogi–congratulate the company for showing leadership by agreeing to share the license for the generic manufacture of its pediatric HIV drug, abacavir, with the Medicines Patent Pool. Launched by UNITAID, the Pool is a system for drug patent holders to license HIV medicines to generic companies.


Read the full press release here.

Back to News page